Silicone Scar Treatment Gels Market

The global Silicone Scar Treatment Gels Market reached USD 2.25 billion in 2025, with a USD 2.41 billion 2026 estimate. Sales are forecast at USD 4.12 billion in 2034, representing a 6.9% CAGR during 2026–2034.

Silicone scar management includes topical, film-forming silicone gels and adhesive silicone gel sheets applied to fully healed skin. Both forms create a protective moisture-retaining interface, although a liquid gel suits facial contours and mobile joints while a sheet provides continuous contact over accessible flat areas. The market includes sales through medical supply channels, retail pharmacies and online outlets; laser procedures, corticosteroid injections, non-silicone onion-extract creams and unrelated acute-wound dressings fall outside its revenue boundary.

The American Academy of Dermatology describes silicone gel sheets and topical preparations as options for raised scars after injury or surgery. It also notes that sheets may outperform ointments in some settings, a qualification that matters when selecting treatment formats. The evidence is strongest for hypertrophic and keloid scarring rather than depressed atrophic acne pits. Product instructions from ScarAway, NewGel+ and Leeds Teaching Hospitals consistently restrict use to intact, closed skin rather than open wounds.

A 2025 randomized study of 96 patients with postoperative eyelid incisions found no significant difference between silicone gel and petrolatum for the evaluated outcomes. Another small 2025 randomized study involving 10 nasolabial flap patients favored topical gel over silicone sheets on several scar measures. These different findings indicate that treatment location, comparator, scar maturity and study size affect clinical interpretation; purchasing decisions therefore combine clinician advice with practical considerations such as adherence, wear time and irritation.

Specialist suppliers distinguish silicone-based products through rapid drying, washable sheet formats, vitamin-containing formulations and region-specific patient instructions. Stratpharma markets a transparent film-forming scar gel, M - lnlycke supplies a self-adherent silicone dressing, and Rej - vaskin pairs topical gel with nighttime sheeting. Repeated applications over several months make refill frequency and adherence commercially important, while hospital burn units and outpatient plastic-surgery services continue to influence initial product choice.

Source: American Academy of Dermatology; 2025 eyelid trial; 2025 gel-versus-sheet trial; NHS silicone gel guidance.

Revenue covers silicone-based scar-management products sold for intact, healed skin, including topical polymer gels and reusable silicone gel sheets. All four segmentation axes describe the same manufacturer-level product revenue from different commercial perspectives.

Surgery creates a recurring pool of newly healed scars

Patients leaving operating theatres with closed incisions often receive scar-care instructions during follow-up visits, creating demand for products used well after the acute wound has healed. Silicone is used for selected raised scars after surgical procedures, including reconstructive operations and caesarean sections. ScarAway supplies a longer-format sheet specifically for C-section scars, while NewGel+ markets gel for mobile or visible locations. Treatment lasting multiple weeks makes product replenishment commercially relevant, but clinicians must first confirm complete epithelial closure and exclude infection or irritated skin.

Clinical evidence supports selected uses but remains heterogeneous

A 2023 systematic review screened 359 publications and retained 30 randomized studies of silicone-based products for postoperative scars. Most trials found improvement in at least one scar characteristic, although inadequate controls and small samples limited certainty. The American Academy of Dermatology describes topical silicone and sheeting as options for raised scars; a 2025 eyelid-incision study found no advantage over petrolatum. This variability restrains universal claims and encourages suppliers to identify appropriate scar types, treatment windows and patient-reported outcomes rather than advertising identical results for every scar.

Adherence and skin tolerance shape realized demand

Liquid gels may be applied twice daily, while reusable sheets require cleaning, gradual wear-time increases and periodic replacement. Leeds Teaching Hospitals advises use only on healed skin and stopping if irritation develops. The daily routine can be difficult for children, patients with sensitive skin or people managing large burn scars. ScarAway recommends 60–90 days of treatment and NewGel+ discusses longer courses for older scars. Suppliers compete on drying time, comfort, discretion and application instructions because discontinuation reduces repeat purchases even when a product is clinically appropriate.

Premium pricing encounters pharmacy competition

Scar gels and sheets are frequently bought without a prescription, exposing branded products to comparison shopping in physical pharmacies and online stores. Rej - vaskin lists a 30-mL silicone gel at USD 52.95, while NewGel+ lists a 15-g vitamin E formulation at USD 35.00 on their U.S. direct-sales sites. These are retail list prices, not global average selling prices. Differences in pack size, ingredient composition and use duration complicate price comparisons, and lower-cost products can capture volume in markets where scar improvement is not routinely reimbursed.

Different scar biology limits the addressable indication

Hypertrophic scars remain within the original wound boundary, whereas keloids can extend beyond it and often require additional interventions. Silicone-based products are used to manage symptoms and appearance of these raised scars, but deep atrophic acne scars typically require a different therapeutic approach. A 2025 comparative trial found added benefit from laser treatment combined with silicone gel for selected postoperative hypertrophic scars. Product sellers therefore face substitution from laser therapy, injections and surgery when topical care alone is insufficient; severe lesions need professional assessment rather than unsupported claims of complete removal.

Source: American Academy of Dermatology; Leeds Teaching Hospitals; PubMed indexed randomized studies; ScarAway; NewGel+; Rej - vaskin.

Thin-film gels compete with reusable sheet technology

Strataderm forms a transparent, gas-permeable silicone film after application, whereas M - lnlycke Mepiform and Advancis Advasil Conform are contact-layer dressings. Product selection depends on scar geometry, ease of securing a dressing, patient occupation and tolerance of adhesive materials. Rej - vaskin recommends gel during daytime and sheeting overnight as distinct use periods. This differentiation is commercially meaningful because facial incisions and mobile joints favor unobtrusive topical films, while flat scars may accommodate a washable dressing. Both silicone formats require fully healed skin, and manufacturer instructions limit application to intact tissue rather than open wounds.

Combination care is attracting new clinical study

A February 2025 comparative study from Egypt examined silicone gel with a 577-nm diode laser for postoperative hypertrophic scars and reported greater improvement in the combined-treatment arm. A 2026 meta-analysis of 45 randomized trials compared silicone gel plus laser against single therapies, while also identifying a high risk of bias in most included studies. Such work supports clinician interest in combining modalities for selected patients but does not establish universal superiority. Device manufacturers and dermatology clinics can use these findings to refine care pathways without classifying laser fees as silicone-product revenue.

Dexpanthenol combinations extend formulation choice

Bayer reported an August 2026 single-arm, open-label evaluation of a dexpanthenol-containing silicone gel with a massage applicator in 55 adults and children. After eight weeks, measured scar appearance scores improved, but the absence of a randomized control limits comparative claims. Rej - vaskin offers silicone with vitamin C derivatives and emollients, while NewGel+ markets a silicone-and-vitamin-E formulation. Ingredient combinations provide brand differentiation and may influence texture and user preference; evidence for an added ingredient must be judged separately from evidence for the silicone barrier itself.

Hospital guidance emphasizes timing and safe wear

Leeds Teaching Hospitals updated patient guidance in June 2025 for liquid silicone gel, reusable sheets and molded silicone. The documents distinguish thin twice-daily topical application from gradual sheet wear, cleaning routines and warning signs of irritation. Leicester NHS guidance reviewed in April 2025 similarly advises that Advasil Conform sheets be applied only to healed scars. These specific instructions favor products with clear labeling and clinician training materials. Consistent guidance can improve adherence and prevent inappropriate application over open wounds, especially during burn rehabilitation.

Evidence quality is becoming a purchasing criterion

The 2025 randomized eyelid trial involving 96 patients did not show a meaningful difference between silicone gel and petrolatum, while a separate 10-patient nasolabial flap comparison favored gel over sheeting. Both are directly relevant to purchase decisions but cover different anatomical sites and have different sample sizes. A 2026 fluid-silicone review adds another evidence synthesis for hypertrophic scar prevention and treatment. Buyers increasingly need indication-specific evidence, standardized scar scales and balanced claims rather than assuming that one gel formulation performs identically across every scar type and patient population.

The treatment pathway starts after skin closure, not at the moment of injury. Silicone products may improve comfort and the appearance of raised scars, but evidence strength varies by comparator, anatomy and scar maturity. The distinction between hypertrophic scars, keloids and atrophic defects is central to responsible product selection.

For raised hypertrophic scars, clinicians commonly consider silicone products after complete epithelial healing and may combine them with pressure therapy or procedural treatments. The 2025 pediatric scar guideline recommends topical silicone gel for established scars to relieve itching, pain and redness, and gives greater priority to sheets or tapes for well-healed wounds in some preventive circumstances. A 2020 hand-burn trial found improvements in selected scar measures when silicone was used alongside pressure garments, without clear superiority of gel over sheets on the Vancouver Scar Scale.

For keloids, a silicone barrier may help appearance or symptoms but often cannot replace intralesional or other specialist treatment. The American Academy of Dermatology discusses silicone among several management options, not as a definitive cure. For depressed atrophic acne scars, the revenue boundary excludes microneedling, resurfacing and filler procedures. Clinicians should review irritation, maceration and adhesive sensitivity; product instructions from M - lnlycke and NHS teams explicitly describe when to stop treatment and seek advice.

Clinical studies also demonstrate why one outcome measure cannot represent the entire category. The 2025 eyelid trial compared silicone gel with petrolatum and found no significant difference in assessed endpoints; the small nasolabial flap trial used a gel-versus-sheet comparison and reported different results. A 2026 Bayer-sponsored exploratory study followed scar appearance over eight weeks without a control group. These designs answer different questions, and the commercial value of new studies depends on whether their results translate to a clearly defined scar population and product format.

Two product formats serve different scar shapes and daily routines: Topical Silicone Scar Treatment Gels dry to a film, while Silicone Gel Sheets deliver a reusable adhesive contact surface. Both use a silicone barrier on closed skin, and each finished product is assigned to exactly one type.

Through 2034, topical film-forming products are expected to retain value leadership, while gel sheets remain important for burn rehabilitation and scar prevention after surgery. Product performance claims require scar-specific evidence, and both formats should be used only after the skin is fully healed.

Application refers to the setting of actual use rather than the retail channel. Home Use, Hospitals, Dermatology Clinics and Other Clinical Settings are mutually exclusive settings for assigning the same product revenue once, even when a clinician first recommends a product that a patient later applies at home.

Home Use should remain the largest application because most daily treatment takes place outside institutions. Hospitals and dermatology clinics retain influence over product choice, especially for high-risk raised scars and patients requiring pressure therapy or additional procedures.

End User groups patients by the principal origin of the scar being treated: Post-Surgical Patients, Burn and Trauma Patients, and Other Scar-Care Consumers. Each treated scar is assigned to one origin category, preventing the same patient purchase from appearing under multiple end-user labels.

The post-surgical category is expected to retain the largest share as incision aftercare becomes more standardized. Burn rehabilitation creates a smaller but specialist-led demand pool, while other consumers remain more exposed to online claims and price comparison.

Scar Type is a clinical classification separate from application setting and product format. Hypertrophic Scars, Keloid Scars and Other Scars and Preventive Use are assigned once based on the primary indication at purchase; the final category does not assume that depressed atrophic scars respond like raised lesions.

Hypertrophic scars are an established target for silicone products in dermatology guidance and post-surgical rehabilitation. Keloids require more complex management, while preventive purchasing depends on procedure-specific evidence and a careful distinction between healed raised scars and depressed atrophic defects.

Regional demand reflects surgical aftercare, access to dermatology and burn services, distribution of premium consumer brands and local guidance on silicone scar management. Market shares are revenue allocations rather than patient-prevalence measures; North America leads while Europe and Asia-Pacific supply substantial clinical and retail demand.

Silicone scar products are obtained through a mix of clinician-directed medical supply and consumer channels. A product may be recommended in a hospital but purchased later through a pharmacy or online shop; the sale is counted only once, while the application setting records where treatment is actually used.

Retail access is supported by a broad range of pack sizes and formulations. ScarAway sells a transparent silicone gel in two sizes and a separate combination kit, while NewGel+ lists vitamin E gel and reusable silicone dots. Rej - vaskin markets topical gel with vitamin C derivatives and an optional sheet routine. These offerings compete on user experience and product presentation, but online prices are retail examples rather than manufacturer net sales or a reliable basis for regional revenue allocations. Patients often need multiple packs over a full course, making refill convenience commercially important.

Clinical channels add value by screening for appropriate indications and explaining safety precautions. Leeds Teaching Hospitals instructs patients to use silicone only after complete wound healing and to stop when irritation occurs. M - lnlycke advises discontinuing Mepiform if persistent maceration or rash develops, and Advancis describes regular sheet cleaning. Such directions reduce misuse, especially in burn rehabilitation or where compression garments are worn. A dressing suitable for a flat healed scar may be inconvenient on a mobile joint, while a gel may be easier to apply but require more frequent daily attention.

Coverage and reimbursement cannot be assumed to be uniform across countries. Some patients receive specialist scar products during rehabilitation, whereas cosmetic aftercare is frequently purchased privately. Market value is influenced by premium branding, product longevity, regional price differences and adherence rather than scar prevalence alone. Clinicians may recommend alternative procedures for difficult keloids or depressed atrophic scars, limiting the addressable product revenue. Suppliers that publish balanced evidence, practical instructions and clear warnings can improve continuity without overstating comparative efficacy.

Source: Leeds NHS; ScarAway; M - lnlycke.

Competition in silicone scar management spans consumer scar brands, medical-device dressings and specialist topical formulations. Alliance Pharma’s ScarAway markets gels, sheets and combined packs, while Newmedical Technology sells NewGel+ formulations and Rej - vaskin positions Rej - vaSil for facial and post-operative care. M - lnlycke Mepiform and Advancis Advasil Conform target reusable silicone-contact dressing needs in clinical and home settings. Product differentiation depends on adhesion, wear time, skin tolerance, drying characteristics and packaging rather than a single universal efficacy claim.

Clinical evidence can favor different formats depending on the scar. The 2025 ten-person nasolabial flap comparison reported better scar scores with topical gel than sheeting, but its limited sample restricts generalization. The 2025 eyelid-surgery randomized study found no significant advantage of gel over petrolatum. A 2026 meta-analysis of combined laser and silicone treatment identified high risk of bias in most included trials. Companies should therefore substantiate indication-specific claims and avoid presenting a single trial as proof of superiority across surgical, burn and acne-related scarring.

Bayer is developing consumer scar-care differentiation around dexpanthenol-containing silicone gel and a massage applicator. Its August 2026 release described an exploratory 55-person study with improvements in appearance scores, while clearly acknowledging the absence of a control group. NewGel+ markets a vitamin E formulation, and Rej - vaskin includes vitamin C derivatives in its gel. Ingredient combinations and application experience can support premium positioning, although controlled studies are needed to establish incremental benefits over a standard silicone barrier.

M - lnlycke and Advancis provide reusable silicone-contact dressings with explicit cleaning and skin-tolerance instructions. Advancis markets Advasil Conform as a reusable silicone gel sheet with a polyurethane outer layer, while M - lnlycke specifies Mepiform for healed hypertrophic and keloid scars. NHS guidance provides practical cleaning and irritation monitoring instructions that influence clinician recommendations. Retail brands instead compete on transparent appearance, pack convenience and online availability. The two channels overlap because many patients begin with professional advice and subsequently purchase products directly.

Competitive boundaries exclude generic wound hydrogels without a silicone scar-management indication and exclude laser, injection and surgical procedure revenue. Manufacturer sales are counted once despite wholesalers and retailers participating in distribution. A company that sells both silicone gel and sheet formats can participate in both product types, but its total in-scope revenue is not duplicated. The broad availability of substitute scar-care options and limited high-quality comparative evidence constrain sustained price premiums through 2034.

• Alliance Pharma plc (ScarAway and Kelo-Cote)
• Biodermis Corporation
• M - lnlycke Health Care AB
• Smith & Nephew plc
• Stratpharma AG
• Rej - vaskin
• Newmedical Technology, Inc. (NewGel+)
• Bayer AG
• Advancis Medical
• Medline Industries, LP

Silicone scar management revenue is projected to increase from USD 2.41 billion in 2026 to USD 4.12 billion in 2034, equivalent to a 6.9% CAGR. Demand depends on appropriate use after wound closure, sustained adherence, retail access and the balance between topical films and reusable sheets.

Postoperative follow-up is expected to remain the largest source of new silicone scar-care users. Patients who receive instructions at the point of wound closure may continue buying topical gel or sheets for several months, particularly when scars are raised, itchy or located on visible skin. The 2025 pediatric guideline and NHS patient leaflets support selected silicone use after healing, but clinicians must distinguish hypertrophic lesions from depressed atrophic scars. Demand is therefore linked to suitable patient selection and repeat use, not simply to total surgical procedure counts.

Topical silicone films are likely to retain a leading share because they are discreet on the face, hands and moving joints. Stratpharma, ScarAway, Rej - vaskin and NewGel+ sell formulations differentiated by drying behavior, application frequency and additional ingredients. Reusable silicone sheets remain important in burn rehabilitation and after certain operations; M - lnlycke and Advancis provide medical contact products with defined wear and cleaning instructions. Neither format should be represented as uniformly superior because the clinical trials reviewed here report different results for different scar sites and comparators.

Silicone gel pricing differs across pharmacy channels, national markets and pack sizes, as shown by supplier listings. North American premium brands have extensive consumer-facing product information, whereas hospital procurement and patient purchasing power exert greater influence in many emerging markets. Online ordering can improve refill access but also increases exposure to exaggerated cosmetic claims. Manufacturers can differentiate through clear safety information, published studies, consistent product availability and formats that patients can tolerate for weeks. Severe keloids and depressed acne scars often require specialist alternatives, which constrains the share of total scar-treatment spending attributable to silicone products.

The 2025 eyelid and nasolabial trials already show why product positioning requires scar-specific comparative clinical evidence. A 2026 meta-analysis examined combined silicone and laser treatment, and Bayer reported an exploratory dexpanthenol-silicone study in 2026. These findings provide additional information for selected use cases without establishing that every combination outperforms standard care. Through 2034, suppliers with credible indication-specific evidence, dependable distribution and practical adherence support are positioned to benefit from growing post-surgical aftercare demand, while substitution and variable reimbursement moderate revenue growth.

Coverage measures silicone-based scar gels and silicone gel sheets sold for healed skin, with one consistent 2025–2034 revenue boundary.